• SII to seek emergency use authorisation for AstraZeneca Covid vaccine in 2 weeks: Poonawalla
    New Delhi, Novèmber 28 (IANS): The Serum Institute of India (SII) will seek emergency use authorisation for the AstraZeneca Covid 19 vaccine in about two weeks. Adar Poonawalla, Founder and CEO, SII said on Saturday that SII is in the process of submitting the data for the clinical trials to the DCGI and will seek emergency use authorisation. He said there will be no delays in the AstraZeneca vaccine rollout as the trials are more than enough for establishing efficacy and
  • Q&A: Where are we in the COVID-19 vaccine race?
    Reuters Drugmakers and research centres around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway. The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic that has claimed more than 1.34 million lives worldwide: Who is furthest along? U.S. drugmaker Pfizer Inc and German partner BioNTech SE released final late-stage trial da
  • AstraZeneca says COVID-19 'vaccine for the world' can be 90% effective
    LONDON, November 23 (Reuters) - AstraZeneca said on Monday its COVID-19 vaccine could be around 90% effective, giving the world's fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals. The British drugmaker said it will have as many as 200 million doses by the end of 2020, around four times as many as U.S. competitor Pfizer. Seven hundred million doses could be ready globally as soon as the end of the fir
  • AstraZeneca COVID-19 vaccine can be 90% effective, results show
    LONDON, November 23 (Reuters): AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen. "This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," Pascal Soriot, Astra's chief executive, said in a statement. The British drugmaker's preliminar
  • Oxford's COVID-19 vaccine trial results 'definitely' before Christmas - investigator
    LONDON, November 19 (Reuters): Results of late-stage trials of University of Oxford's COVID-19 vaccine candidate should definitely be known by Christmas, the chief investigator on the study said on Thursday, adding it was too early to know its efficacy yet. Asked if it was too early to say whether the vaccine, which is licensed to AstraZeneca, stops disease developing, Andrew Pollard, director of the Oxford Vaccine Group, said: "We haven't quite got to that point y
  • Vaccine hopes rise as Oxford jab prompts immune response among old as well as young adults
    LONDON, October 26 (Reuters): One of the world's leading COVID-19 experimental vaccines produces an immune response in both young and old adults, raising hopes of a path out of the gloom and economic destruction wrought by the novel coronavirus. The vaccine, developed by the University of Oxford, also triggers lower adverse responses among the elderly, British drug maker AstraZeneca Plc, which is helping manufacture the vaccine, said on Monday. A vaccine that works is se
  • COVID-19 vax to be rolled out within 3 months in UK: Report
    London, October 4 (IANS): The COVID-19 vaccine developed by scientists at the Oxford University, which is advanced stages of the trial, could be rolled out in as little as three months in the UK, a report said. According to the Times, a mass roll-out of a coronavirus vaccine could be completed in as little as three months, raising the prospect of every adult in the country receiving a jab as early as Easter. Scientists working on the Oxford vaccine hope it could be approved by re
  • AstraZeneca resumes Covid vaccine trials in UK
    New Delhi, September 12 (IANS): Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so. On September 6, the standard review process had triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees and international regulators. The UK committee has concluded its investigations a
  • AstraZeneca vaccine trial pause a 'wake-up call', says WHO
    ZURICH, September 10 (Reuters): AstraZeneca's pause of an experimental vaccine for the coronavirus after the illness of a participant is a "wake-up call" but should not discourage researchers, the World Health Organization's (WHO) chief scientist said on Thursday. "This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva. &
  • Serum Institute pauses Covid vax trials in India
    MUMBAI, September10 (Reuters):  Serum Institute of India has put on hold trials of AstraZeneca's potential COVID-19 vaccine in the country until the British drugmaker restarts them, the company said on Thursday. "We are reviewing the situation and pausing India trials," Serum, the world's biggest vaccine manufacturer by volume, said in a brief statement. AstraZeneca said on Tuesday it had paused trials of its experimental coronavirus vaccine following an un
  • Covid vaccine likely by year end: AstraZeneca
    New Delhi, September 10 (ANI): AstraZeneca CEO Pascal Soriot on Wednesday expressed hopes that a vaccine against the novel coronavirus developed by the pharmaceutical company would be ready by the end of 2020 or early 2021, despite having to pause clinical trials. Earlier this week, the UK-Swedish company reportedly froze the trials after discovering that one participant was sick with transverse myelitis. This condition results in the inflammation of parts of the spinal cord and may
  • AstraZeneca should know by year-end whether vaccine works if trials restart
    ZURICH/FRANKFURT (Reuters): AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against COVID-19, the drugmaker's chief executive Pascal Soriot said on Thursday, as long as it can resume trials soon. The British company suspended late-stage trials this week after an illness in a participant in Britain. The patient was reportedly suffering from symptoms associated with a rare spinal inflammatory disorder called transverse
  • AstraZeneca Covid vax reaches Phase-3 trial in US
    New York, September 1 (IANS): The Covid-19 vaccine candidate developed by Oxford University in partnership with the UK-based global biopharmaceutical company AstraZeneca has reached Phase-3 trial in the US. The trial will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine, known as AZD1222, can prevent symptomatic Covid-19, the US National Institutes of Health (NIH) said on Monday. "Positive results from preclinical resear
  • EU pays 336 million euros to secure AstraZeneca's potential COVID-19 vaccine
    BRUSSELS, August 27 (Reuters): The European Commission has made a 336 million euros ($396 million) downpayment to British drug maker AstraZeneca to secure at least 300 million doses of its potential COVID-19 vaccine, a spokesman said on Thursday. The deal covers development, liability and other costs faced by the vaccine maker. The EU has also secured an option to buy 100 million additional doses of the vaccine under development. The 27 EU states could buy it at a later stag
  • Serum to produce up to 100 mn Covid vaccine doses for India, others
    New Delhi, August 7 (PTI): Serum Institute of India on Friday said it has entered into a new partnership with international vaccine alliance Gavi and Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of COVID-19 vaccines for India as well as other low and middle-income countries. "The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains
  • Oxford COVID-19 vaccine promising: Scientists
    New Delhi, July 21 (PTI): The coronavirus vaccine developed by Oxford University and AstraZeneca shows promise as it can generate both antibodies and cell-mediated immune responses, say several scientists in India and abroad, while cautioning that there is still a long way to go.       "Very promising", "comforting" and "interesting" were some of the reactions from the scientific community a day after The Lancet revealed the vaccine a
  • Possible but not certain COVID-19 vaccine rolled out this year - Oxford developer
    LONDON, July 21 (Reuters): The University of Oxford's possible COVID-19 vaccine could be rolled out by the end of the year but there is no certainty that will happen, the lead developer of the vaccine said on Tuesday. The experimental vaccine, which has been licensed to AstraZeneca, produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could be in use by the end of the year. "The end of the year target for getting vac
  • SII to apply for Oxford vaccine trials in India in a week
    New Delhi, July 20 (IANS) The Serum Institute of India (SII) will soon apply to the Indian regulator for the licensure trials of the AstraZeneca-Oxford Covid vaccine.   Commenting on the AstraZeneca-Oxford vaccine's results, Adar Poonawalla, CEO, Serum Institute of India, said, "The trials have shown promising results and we are extremely happy about it. We will be applying for the licensure trials to the Indian regulator in a week's time. As soon as they grant
  • Russia, despite theft allegations, says deal to make UK-developed COVID-19 vaccine is on
    MOSCOW, July 17 (Reuters): Russia will unveil a deal with AstraZeneca to manufacture a COVID-19 vaccine being developed by the pharmaceuticals giant and Oxford University, its wealth fund head said on Friday, adding this showed Moscow had no need to steal vaccine data.   Britain, Canada and the United States said on Thursday that hackers backed by the Russian state were trying to steal COVID-19 vaccine and treatment research from academic and pharmaceutical institutions
  • AstraZeneca, Moderna ahead in COVID-19 vaccine race - WHO
    GENEVA, June 26 (Reuters): AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.   The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.   This week, AstraZeneca signed its tenth supply-and-manufacturing deal.